US‑listed psychedelic stocks jumped on Monday after President Trump ordered faster FDA reviews, sparking sharp, uneven rallies among developers of treatments for depression, PTSD and addiction.
Market reaction: sharp, uneven gains
Trading on Monday showed big moves across several US‑listed psychedelic developers. Shares of several firms rose sharply, with some names jumping double‑ or triple‑digit percentages while others moved more modestly. Companies in focus included Compass Pathways, AtaiBeckley, Definium Therapeutics, Enveric BioSciences, GH Research and Cybin.
Volume spiked as investors re‑priced the odds that regulators will speed up approvals for compounds being studied to treat depression, post‑traumatic stress disorder and addiction. One analyst said the rally could be the start of a sustained re‑rating for the sector; another called the move a formal political endorsement of psychedelic therapies.
What the executive order does
The White House order directs the Food and Drug Administration to prioritise reviews of psychedelic drugs that hold breakthrough therapy designations and to consider granting priority vouchers in certain cases. It also asks the Drug Enforcement Administration to design a system allowing patients to access investigational psychedelic medicines while those medicines remain under regulatory review.
The order singled out the mental health challenges facing veterans and asked the Department of Veterans Affairs to push for greater clinical‑trial participation. It also included federal research funding for psychedelic compounds, including ibogaine.
Analysts see lower regulatory risk and faster timelines
Jay Olson, an analyst at Oppenheimer, wrote that the move "represents a structural inflection for the [U.S.] psychedelics sector by facilitating research, regulatory timelines, and patient access." He and his team flagged AtaiBeckley, Compass Pathways and Definium Therapeutics as companies with "differentiated advantages" under the new framework.
Analysts' aggregated ratings on those firms are broadly positive, with many covering the sector assigning buy ratings and implying significant upside from current levels, according to industry estimates.
How regulators could move faster
The executive order asks the FDA to fast‑track psychedelic compounds that receive a breakthrough therapy designation, which could shorten review windows for those applications. One mechanism in the order would allocate so‑called national priority vouchers to certain drugs, which can compress review time for priority cases compared with standard fast‑track timelines.
That timeline has encouraged some investors to take a more bullish stance on companies with late‑stage programmes.
Industry and political voices react
Industry executives welcomed the move, reflecting hopes it will hasten research and patient access.
Related Articles
- Housing supply splits Australia's property market
- Okta shares surge as identity security heats up
- Emerging-market currencies slip as Strait of Hormuz tensions push up oil
Officials said regulators could make decisions on the drugs as soon as this summer.
This article was created with AI assistance.
